Intermediate impacts of COVID-19 lockdowns on surgical glaucoma cases in Quebec, Canada: insights from a tertiary eye center.

IF 1.8 4区医学 Q2 OPHTHALMOLOGY

International journal of ophthalmology Pub Date : 2025-10-18 eCollection Date: 2025-01-01 DOI:10.18240/ijo.2025.10.11

Huixin Anna Zhang, Sarah McIntyre, Yosra Er-Reguyeg, Andrew Toren

{"title":"Intermediate impacts of COVID-19 lockdowns on surgical glaucoma cases in Quebec, Canada: insights from a tertiary eye center.","authors":"Huixin Anna Zhang, Sarah McIntyre, Yosra Er-Reguyeg, Andrew Toren","doi":"10.18240/ijo.2025.10.11","DOIUrl":null,"url":null,"abstract":"Aim: To assess the effect of the coronavirus disease 2019 (COVID-19) pandemic on the wait times and severity of surgical glaucoma cases in a single tertiary referral center in Quebec, Canada.Methods: Preoperative severity data included mean visual field (VF) deficit, intraocular pressure (IOP), the number of topical glaucoma medication classes, and preoperative best corrected visual acuity (BCVA). The times from referral to procedure (referral time) and from listing date to procedure (waitlisting time) were calculated.Results: This retrospective cohort study involved 181 eyes of patients undergoing glaucoma surgery from March 1 to June 30, 2019 (pre-pandemic period), and 201 eyes in the same timeframe in 2021 (pandemic period) at Saint-Sacrement Hospital in Quebec City. There was no significant difference in the severity data of surgical glaucoma across both periods (VF deficit: P=0.48; IOP: P=0.14; BCVA: P=0.24; topical medication classes: P=0.27). The number of patients referred with oral glaucoma medication increased slightly from 45 to 70 in 2019 and 2021 respectively (P=0.08). Delay data were also comparable. Mean referral time was 122±120d in 2019 versus 144±136d in 2021 (P=0.09), whereas waitlisting time before the pandemic was 43±44.5 versus 39±41.8d in 2021 (P=0.13).Conclusion: Despite North America's strictest pandemic restrictions, limited negative impact is observed on waitlisting delays and the severity of glaucoma cases presenting at our center. A larger subset of patients is treated with oral medications indicating a possible increase in advanced glaucoma.","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 10","pages":"1894-1900"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454003/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.10.11","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To assess the effect of the coronavirus disease 2019 (COVID-19) pandemic on the wait times and severity of surgical glaucoma cases in a single tertiary referral center in Quebec, Canada.

Methods: Preoperative severity data included mean visual field (VF) deficit, intraocular pressure (IOP), the number of topical glaucoma medication classes, and preoperative best corrected visual acuity (BCVA). The times from referral to procedure (referral time) and from listing date to procedure (waitlisting time) were calculated.

Results: This retrospective cohort study involved 181 eyes of patients undergoing glaucoma surgery from March 1 to June 30, 2019 (pre-pandemic period), and 201 eyes in the same timeframe in 2021 (pandemic period) at Saint-Sacrement Hospital in Quebec City. There was no significant difference in the severity data of surgical glaucoma across both periods (VF deficit: P=0.48; IOP: P=0.14; BCVA: P=0.24; topical medication classes: P=0.27). The number of patients referred with oral glaucoma medication increased slightly from 45 to 70 in 2019 and 2021 respectively (P=0.08). Delay data were also comparable. Mean referral time was 122±120d in 2019 versus 144±136d in 2021 (P=0.09), whereas waitlisting time before the pandemic was 43±44.5 versus 39±41.8d in 2021 (P=0.13).

Conclusion: Despite North America's strictest pandemic restrictions, limited negative impact is observed on waitlisting delays and the severity of glaucoma cases presenting at our center. A larger subset of patients is treated with oral medications indicating a possible increase in advanced glaucoma.

查看原文本刊更多论文

COVID-19封锁对加拿大魁北克手术青光眼病例的中间影响：来自三级眼科中心的见解

目的：评估2019冠状病毒病（COVID-19）大流行对加拿大魁北克省单一三级转诊中心青光眼手术病例等待时间和严重程度的影响。方法：术前严重程度数据包括平均视野（VF）缺损、眼压（IOP）、局部青光眼用药类别数、术前最佳矫正视力（BCVA）。计算从转介到办理手续的时间（转介时间）和从上市日期到办理手续的时间（等待上市时间）。结果：本回顾性队列研究纳入了2019年3月1日至6月30日（大流行前）在魁北克市圣萨克门医院接受青光眼手术的181只眼睛，以及2021年同期（大流行期间）在魁北克市圣萨克门医院接受青光眼手术的201只眼睛。两期手术青光眼严重程度数据差异无统计学意义（VF缺损：P=0.48; IOP: P=0.14; BCVA: P=0.24；外用药物类别：P=0.27）。接受口服青光眼药物治疗的患者分别从2019年的45例和2021年的70例略有增加（P=0.08）。延迟数据也具有可比性。2019年平均转诊时间为122±120d， 2021年为144±136d (P=0.09)，疫情前平均等待时间为43±44.5 d， 2021年为39±41.8d （P=0.13）。结论：尽管北美有最严格的流行病限制，但对我们中心就诊的青光眼病例的等候延误和严重程度的负面影响有限。更大一部分患者接受口服药物治疗，这表明晚期青光眼可能增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of ophthalmology Medicine-Ophthalmology

CiteScore

2.50

自引率

7.10%

发文量

3141

审稿时长

4-8 weeks

期刊介绍： · International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online). This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed, PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166. IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO); Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President, Chinese Academy of Engineering. International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of AAO/PAAO) et al. Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society). Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press). Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics). Associate Editors-in-Chief include: Prof. Ning-Li Wang (President Elect of APAO); Prof. Ke Yao (President of Chinese Ophthalmological Society) ; Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ; Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA); Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society); Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA); Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA). IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles, both basic and clinical papers. Instruction is Welcome Contribution is Welcome Citation is Welcome Cooperation organization International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.